Want to see FR:ERF full AI Analyst Report?
ERF Stock Chart & Stats
€69.84
€0.48(1.00%)
At close: 4:00 PM EST
€69.84
€0.48(1.00%)
Day’s Range― - ―
52-Week Range€54.86 - €74.32
Previous CloseN/A
Volume42.85K
Average Volume (3M)260.87K
Market Cap
€12.21B
Enterprise Value€15.48B
Total Cash (Recent Filing)€791.00M
Total Debt (Recent Filing)€5.43B
Price to Earnings (P/E)27.9
Beta0.86
Next Earnings
Jul 29, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)2.48
Shares Outstanding176,000,000
10 Day Avg. Volume311,523
30 Day Avg. Volume260,872
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.17
Price to Sales (P/S)1.54
P/FCF Ratio20.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€86.00Price Target Upside23.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)3.77
Revenue Forecast (FY)€7.63B
Bulls Say, Bears Say
Bulls Say
Scale & Diversified Lab NetworkEurofins' broad international lab footprint and diversified end-market coverage (pharma, food, environmental, clinical, consumer) spreads fixed costs across volumes, creates recurring fee-for-service revenue tied to regulation, and reduces exposure to single-industry cyclicality, supporting durable earnings resilience.
Strong 2025 Revenue GrowthA 36.7% revenue increase in 2025 signals robust structural demand or successful organic/bolt-on expansion. Sustained revenue momentum enhances capacity utilization, supports long-term investment in methods and labs, and improves the company's ability to fund scale advantages and absorb fixed costs over the 2–6 month horizon and beyond.
Operating Cash & Core ProfitabilityPositive operating cash flow (~€1.3B) and steady EBITDA margins indicate the core lab services generate recurring cash and operating profitability. This provides strategic flexibility to invest in capacity, support working capital, and sustain operations even if one segment softens, underpinning medium-term financial stability.
Bears Say
Higher LeverageMaterial increase in leverage reduces balance-sheet flexibility and raises refinancing and interest-rate exposure. With debt-to-equity jumping to ~1.53, Eurofins faces higher fixed financial costs and less room to pursue opportunistic investments or absorb earnings volatility without increasing financial strain over the medium term.
Margin Compression & Gross-Margin AnomalyDeclining net margin and an anomalously low reported 2025 gross margin undermine earnings quality and suggest cost pressures, one-offs, or reporting distortions. Persistent margin weakness would erode cash flow and the firm's ability to fund R&D or capex, and it raises uncertainty about sustainable profitability.
Weaker Free Cash Flow ConversionA marked drop in free cash flow and cash conversion ratio points to higher capex or working-capital absorption, reducing internal funding for debt reduction or growth. Lower FCF conversion increases reliance on external financing and limits capacity to deleverage, raising structural financial risk if margins or growth falter.
Eurofins Scientific News
ERF FAQ
What was Eurofins Scientific’s price range in the past 12 months?
Eurofins Scientific lowest stock price was €54.86 and its highest was €74.32 in the past 12 months.
What is Eurofins Scientific’s market cap?
Eurofins Scientific’s market cap is €12.21B.
When is Eurofins Scientific’s upcoming earnings report date?
Eurofins Scientific’s upcoming earnings report date is Jul 29, 2026 which is in 23 days.
How were Eurofins Scientific’s earnings last quarter?
Eurofins Scientific released its earnings results on Jan 29, 2026. The company reported €1.28 earnings per share for the quarter, beating the consensus estimate of €1.26 by €0.02.
Is Eurofins Scientific overvalued?
According to Wall Street analysts Eurofins Scientific’s price is currently Undervalued.
Does Eurofins Scientific pay dividends?
Eurofins Scientific pays a Annually dividend of €0.72 which represents an annual dividend yield of 0.97%. See more information on Eurofins Scientific dividends here
What is Eurofins Scientific’s EPS estimate?
Eurofins Scientific’s EPS estimate is 1.91.
How many shares outstanding does Eurofins Scientific have?
Eurofins Scientific has 176,000,000 shares outstanding.
What happened to Eurofins Scientific’s price movement after its last earnings report?
Eurofins Scientific reported an EPS of €1.28 in its last earnings report, beating expectations of €1.26. Following the earnings report the stock price went down -6.259%.
Which hedge fund is a major shareholder of Eurofins Scientific?
Currently, no hedge funds are holding shares in FR:ERF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
ERF Stock 12 Month Forecast
Average Price Target
€86.00
▲(23.14% Upside)
Technical Analysis
Options Prices
Currently, No data available
---




